226 related articles for article (PubMed ID: 9225172)
1. Mode of action of orlistat.
Guerciolini R
Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S12-23. PubMed ID: 9225172
[TBL] [Abstract][Full Text] [Related]
2. Orlistat reduces gallbladder emptying by inhibition of CCK release in response to a test meal.
Ellrichmann M; Ritter PR; Otte JM; Schrader H; Banasch M; Brunke G; Herzig KH; Seebeck J; Schmidt WE; Schmitz F
Regul Pept; 2007 Mar; 139(1-3):136-40. PubMed ID: 17175037
[TBL] [Abstract][Full Text] [Related]
3. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
[TBL] [Abstract][Full Text] [Related]
4. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers.
Melia AT; Zhi J; Zelasko R; Hartmann D; Güzelhan C; Guerciolini R; Odink J
Eur J Clin Pharmacol; 1998; 54(9-10):773-7. PubMed ID: 9923583
[TBL] [Abstract][Full Text] [Related]
5. Lipase inhibitor orlistat decreases incorporation of eicosapentaenoic and docosahexaenoic acids in rat tissues.
Cruz-Hernandez C; Oliveira M; Pescia G; Moulin J; Masserey-Elmelegy I; Dionisi F; Destaillats F
Nutr Res; 2010 Feb; 30(2):134-40. PubMed ID: 20226999
[TBL] [Abstract][Full Text] [Related]
6. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers.
Zhi J; Melia AT; Eggers H; Joly R; Patel IH
J Clin Pharmacol; 1995 Nov; 35(11):1103-8. PubMed ID: 8626884
[TBL] [Abstract][Full Text] [Related]
7. Influence of dietary composition on the inhibition of fat absorption by orlistat.
Güzelhan C; Odink J; Niestijl Jansen-Zuidema JJ; Hartmann D
J Int Med Res; 1994; 22(5):255-65. PubMed ID: 7867870
[TBL] [Abstract][Full Text] [Related]
8. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake.
Hartmann D; Hussain Y; Güzelhan C; Odink J
Br J Clin Pharmacol; 1993 Sep; 36(3):266-70. PubMed ID: 9114915
[TBL] [Abstract][Full Text] [Related]
9. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study.
Froehlich F; Hartmann D; Guezelhan C; Gonvers JJ; Jansen JB; Fried M
Dig Dis Sci; 1996 Dec; 41(12):2404-8. PubMed ID: 9011450
[TBL] [Abstract][Full Text] [Related]
10. Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis.
Point V; Bénarouche A; Zarrillo J; Guy A; Magnez R; Fonseca L; Raux B; Leclaire J; Buono G; Fotiadu F; Durand T; Carrière F; Vaysse C; Couëdelo L; Cavalier JF
Eur J Med Chem; 2016 Nov; 123():834-848. PubMed ID: 27543878
[TBL] [Abstract][Full Text] [Related]
11. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers.
Zhi J; Melia AT; Guerciolini R; Chung J; Kinberg J; Hauptman JB; Patel IH
Clin Pharmacol Ther; 1994 Jul; 56(1):82-5. PubMed ID: 8033498
[TBL] [Abstract][Full Text] [Related]
12. [Orlistat (Xenical)].
Crenier L; Sternon J
Rev Med Brux; 1999 Jun; 20(3):159-63. PubMed ID: 10429540
[TBL] [Abstract][Full Text] [Related]
13. Role of free fatty acids in regulating gastric emptying and gallbladder contraction.
Degen L; Matzinger D; Drewe J; Nisslé S; Maecke H; Lengsfeld H; Hadvary P; Beglinger C
Digestion; 2006; 74(3-4):131-9. PubMed ID: 17220631
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic equivalence of two orlistat capsule formulations in healthy volunteers under fed conditions.
Di Marco M; Marier JF; Ducharme MP; Morin I; Engel C; Gulbranson S; Thudi NR; Murpani D; Rampal A; Monif T; Koundinya TS; Deo K; Monif T
Int J Clin Pharmacol Ther; 2008 Jun; 46(6):319-26. PubMed ID: 18541129
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat.
Hussain Y; Güzelhan C; Odink J; van der Beek EJ; Hartmann D
J Clin Pharmacol; 1994 Nov; 34(11):1121-5. PubMed ID: 7876405
[TBL] [Abstract][Full Text] [Related]
16. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.
Bryson A; de la Motte S; Dunk C
Br J Clin Pharmacol; 2009 Mar; 67(3):309-15. PubMed ID: 19220279
[TBL] [Abstract][Full Text] [Related]
17. Orlistat inhibits dietary cholesterol absorption.
Mittendorfer B; Ostlund RE; Patterson BW; Klein S
Obes Res; 2001 Oct; 9(10):599-604. PubMed ID: 11595776
[TBL] [Abstract][Full Text] [Related]
18. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers.
Melia AT; Zhi J; Koss-Twardy SG; Min BH; Smith BL; Freundlich NL; Arora S; Passe SM
J Clin Pharmacol; 1995 Aug; 35(8):840-3. PubMed ID: 8522642
[TBL] [Abstract][Full Text] [Related]
19. Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects.
Ahnen DJ; Guerciolini R; Hauptman J; Blotner S; Woods CJ; Wargovich MJ
Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1291-9. PubMed ID: 17920338
[TBL] [Abstract][Full Text] [Related]
20. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients.
Zhi J; Mulligan TE; Hauptman JB
J Clin Pharmacol; 1999 Jan; 39(1):41-6. PubMed ID: 9987699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
